课题基金 / 基金详情

Kinetic High Throughput Screening for Agonists and Inhibitors of the TRPML1 Ion channel

Kinetic High Throughput Screening for Agonists and Inhibitors of the TRPML1 Ion channel
TRPML1 离子通道激动剂和抑制剂的动力学高通量筛选
批准号:
9205759
负责人:
Juan Marugan
金额:
$11.4万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Juan Marugan的其他基金

相似基金

相关文献

中文摘要
翻译
项目亮点:已在初级qHTS中鉴定出调节剂。目前正在开发和优化化学品系列。 在此期间,NCGC促进并保持了与NIH和校外研究人员的180多项积极合作,促进了整个人类疾病谱的药物发现工作。 这些努力已经导致了100多个高通量筛选和近60个药物化学活动,为我们的合作者和一般研究社区提供了丰富的出版物和有前途的小分子线索。 此外,NCGC还承担了一系列信息挑战,以更好地利用现有的药物和疾病靶点信息,并为公众提供易于获取的资源,进一步促进人类疾病新疗法的开发。
英文摘要
Project highlights: modulators have been identified in primary qHTS. Development and optimization of chemical series are currently underway. During this period, the NCGC has fostered and maintained over 180 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to over 100 high-throughput screens and nearly 60 medicinal chemistry campaigns, providing our collaborators and the general research community a wealth of publications and promising small molecule leads. In addition, the NCGC has undertaken a number of informatic challenges to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Small molecule agonists of the relaxin 1 receptor
Identification of Small Molecule that act on gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome
HTS Assay for Identification of Compounds that Reduce PNC Prevalence
Kinetic High Throughput Screening for Agonists and Inhibitors of the TRPML1 Ion channel
海外基金